Aquestive Therapeutics, Inc.
AQST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001398733
In the last 90 days, Aquestive Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 185 institutions reported holding it in 13F filings for Q2 2026, worth $299.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Aquestive Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 2 insiders, $373.5K in total
- Insiders trading
- 2
- Net value
- −$373.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Aquestive Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Barber Daniel | President and CEO | 652,317 | Sep 16, 2026 | 10 |
| Korczynski Sherry | Chief Commercial Officer | 235,689 | Sep 11, 2026 | 5 |
| Boyd Peter E. | Chief People Officer | 284,024 | Sep 10, 2026 | 7 |
| Jung Cassie | Chief Operating Officer | 206,833 | Sep 8, 2026 | 5 |
| Krop Julie | Director | 0 | Jun 24, 2026 | 2 |
| Morris Timothy E | Director | – | Jun 12, 2026 | 1 |
| Brown Gregory B | Director | – | Jun 12, 2026 | 1 |
| Cochran John | Director | – | Jun 12, 2026 | 1 |
| Taglietti Marco | Director | – | Jun 12, 2026 | 1 |
| Jenkins Abigail L. | Director | – | Jun 12, 2026 | 1 |
| Zalewski Thomas A. | Chief Legal Officer | 100,000 | May 19, 2026 | 1 |
| Cioffi Melina | SVP, Regulatory Affairs | 273,200 | May 18, 2026 | 3 |
| Braender Lori J | Corporate Secretary | 231,042 | May 11, 2026 | 4 |
| Toth A Ernest Jr | Chief Financial Officer | 283,460 | May 7, 2026 | 3 |
| Davis Matthew W. | Chief Development Officer | 100,000 | Mar 11, 2026 | 2 |
| Greenhawt Matthew J. | Chief Medical Officer | 75,000 | Mar 11, 2026 | 1 |
| Kraus Carl N | Chief Medical Officer | 282,475 | Oct 17, 2025 | 1 |
| Wargacki Stephen | Chief Science Officer | 343,552 | Mar 11, 2025 | 0 |
| Bratton Douglas K | 10% Owner | 199,841Indirect | Dec 4, 2024 | 0 |
| Schobel Alexander Mark | Chief Innovation/Tech Officer | 980,726 | Oct 2, 2024 | 0 |
| Costa Santo J | Director | – | Jun 21, 2024 | 0 |
| Marshall Ken W. | SVP, Chief Commercial Officer | 150,000 | Aug 9, 2023 | 0 |
| Truitt Kenneth | Chief Medical Officer | – | Sep 8, 2022 | 0 |
| Kendall Keith J | CEO and President | 1,000Indirect | Mar 14, 2022 | 0 |
| Wood Theresa | SVP-HR and Org. Development | – | Mar 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)2:00 PM ET | Sep 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.82 | −$120.5K | −3.7%652.3K after | 10b5-1 |
| Sep 11, 2026 (view filing)11:07 AM ET | Sep 9 | 2 days | Korczynski SherryChief Commercial Officer | SSale | −8.75K | $5.22 | −$45.7K | −3.6%235.7K after | 10b5-1 |
| Aug 18, 2026 (view filing)4:13 PM ET | Aug 17 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.29 | −$107.2K | −4.1%585.6K after | 10b5-1 |
| Jul 17, 2026 (view filing)1:15 PM ET | Jul 15-16 | 2 days | Barber DanielPresident and CEO | SSale | −25.0K | $4.01 | −$100.2K | −3.9%610.6K after | 2 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Krop JulieDirector | SSale | −25.0K | $5.02 | −$125.5K | −100.0%0 after | 10b5-1 |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.16 | −$104.0K | −3.8%635.6K after | 10b5-1 |
| May 18, 2026 (view filing) | May 15 | 3 days | Barber DanielPresident and CEO | SSale | −8.26K | $4.29 | −$35.4K | −1.2%660.6K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Boyd Peter E.Chief People Officer | SSale | −29.8K | $4.17 | −$124.3K | −8.1%338.5K after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Barber DanielPresident and CEO | SSale | −180.7K | $4.17 | −$753.4K | −15.2%1.00M after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Braender Lori JChief Legal Officer | SSale | −40.1K | $4.17 | −$167.2K | −8.3%442.9K after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Cioffi MelinaSVP, Regulatory Affairs | SSale | −25.3K | $4.17 | −$105.5K | −8.4%274.9K after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Toth A Ernest JrChief Financial Officer | SSale | −58.3K | $4.17 | −$242.9K | −13.4%376.1K after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Korczynski SherryChief Commercial Officer | SSale | −15.7K | $4.17 | −$65.6K | −6.1%241.1K after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Jung CassieChief Operating Officer | SSale | −45.8K | $4.17 | −$190.9K | −14.3%275.0K after | |
| Oct 17, 2025 (view filing) | Oct 15 | 2 days | Jung CassieChief Operating Officer | SSale | −67.6K | $7.01 | −$473.7K | −21.9%240.8K after | 10b5-1 |
| Oct 17, 2025 (view filing) | Oct 15 | 2 days | Kraus Carl NChief Medical Officer | SSale | −20.3K | $7.00 | −$141.9K | −6.7%282.5K after | 10b5-1 |
| Oct 17, 2025 (view filing) | Oct 15 | 2 days | Boyd Peter E.See Remarks | SSale | −10.0K | $7.00 | −$70.0K | −3.6%268.3K after | 10b5-1 |
| Sep 29, 2025 (view filing) | Sep 26 | 3 days | Barber DanielPresident and CEO | SSale | −91.3K | $6.03 | −$550.8K | −9.0%923.4K after | 10b5-1 |
| Sep 29, 2025 (view filing) | Sep 26 | 3 days | Boyd Peter E.See Remarks | SSale | −10.0K | $6.30 | −$63.0K | −3.5%278.3K after | 10b5-1 |
| Sep 22, 2025 (view filing) | Sep 19 | 3 days | Barber DanielPresident and CEO | SSale | −400 | $6.00 | −$2.40K | 0.0%1.01M after | 10b5-1 |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Jung CassieChief Operating Officer | SSale | −62.2K | $5.00 | −$310.9K | −18.0%283.3K after | 10b5-1 |
| Sep 8, 2025 (view filing) | Sep 5 | 3 days | Boyd Peter E.See Remarks | SSale | −15.0K | $5.30 | −$79.5K | −4.9%288.3K after | 10b5-1 |
| Nov 27, 2024 (view filing) | Nov 26 | 1 day | Jung CassieChief Operating Officer | SSale | −44 | $4.87 | −$214.28 | −100.0%0 after | |
| Mar 19, 2024 (view filing) | Mar 15 | 4 days | Schobel Alexander MarkChief Innovation/Tech Officer | SSale | −50.0K | $6.00 | −$300.0K | −4.8%984.5K after | 10b5-1 |
| Jun 15, 2022 (view filing) | Jun 14 | 1 day | Boyd Peter E.SVP-Bus. Process & Info. Tech. | PPurchase | +5.00K | $0.81 | +$4.05K | +9.2%59.5K after | |
| Jun 10, 2022 (view filing)5:27 PM ET | Jun 8 | 2 days | Barber DanielChief Executive Officer | PPurchase | +91.7K | $0.96 | +$88.1K | +90.0%193.7K after | |
| Jun 10, 2022 (view filing)5:27 PM ET | Jun 8 | 2 days | Barber DanielChief Executive Officer | PPurchase | +91.7K | $0.13 | +$11.9K | –91.7K after | Derivative |
| Jun 10, 2022 (view filing)5:26 PM ET | Jun 8 | 2 days | Schobel Alexander MarkChief Innovation/Tech Officer | PPurchase | +45.9K | $0.96 | +$44.0K | +5.5%882.9K after | |
| Jun 10, 2022 (view filing)5:26 PM ET | Jun 8 | 2 days | Schobel Alexander MarkChief Innovation/Tech Officer | PPurchase | +45.9K | $0.13 | +$5.96K | –45.9K after | Derivative |
| Jun 10, 2022 (view filing)5:26 PM ET | Jun 8 | 2 days | Boyd Peter E.SVP-Bus. Process & Info. Tech. | PPurchase | +2.29K | $0.96 | +$2.20K | +4.4%54.5K after | |
| Jun 10, 2022 (view filing)5:26 PM ET | Jun 8 | 2 days | Boyd Peter E.SVP-Bus. Process & Info. Tech. | PPurchase | +2.29K | $0.13 | +$298.09 | –2.29K after | Derivative |
| Jun 10, 2022 (view filing)5:26 PM ET | Jun 8 | 2 days | Braender Lori JGeneral Counsel | PPurchase | +13.8K | $0.96 | +$13.2K | +55.0%38.8K after | |
| Jun 10, 2022 (view filing)5:26 PM ET | Jun 8 | 2 days | Braender Lori JGeneral Counsel | PPurchase | +13.8K | $0.13 | +$1.79K | –13.8K after | Derivative |